Funder
Certara Strategic Consulting
Kite Pharma
Publisher
Springer Science and Business Media LLC
Reference41 articles.
1. US FDA. US prescribing information: Yescarta (axicabtagene ciloleucel). Santa Monica (CA): Kite Pharma, Inc; 2022. Available from: https://www.fda.gov/media/108377/download. Accessed 31 Jan 2023.
2. King AC, Orozco JS. Axicabtagene ciloleucel: the first FDA-approved CAR T-cell therapy for relapsed/refractory large B-cell lymphoma. J Adv Pract Oncol. 2019;10:878–82.
3. Westin JR, Kersten MJ, Salles G, Abramson JS, Schuster SJ, Locke FL, et al. Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed/refractory aggressive B-cell lymphomas: observations from the JULIET, ZUMA-1, and TRANSCEND trials. Am J Hematol. 2021;96:1295–312.
4. Wang K, Wei G, Liu D. CD19: a biomarker for B cell development, lymphoma diagnosis and therapy. Exp Hematol Oncol. 2012;1:36.
5. Sadelain M, Brentjens R, Rivière I. The basic principles of chimeric antigen receptor design. Cancer Discov. 2013;3:388–98.